Joseph Thomas's questions to Travere Therapeutics Inc (TVTX) leadership • Q3 2024
Question
Joseph Thomas of Scotiabank inquired about Travere's efforts and opportunities to encourage earlier diagnosis and treatment of IgAN, particularly in light of the recent draft KDIGO guideline update.
Answer
Chief Commercial Officer Peter Heerma responded, referencing earlier remarks by CMO Dr. Jula Inrig about FILSPARI's benefits in patients with lower proteinuria. He noted a greater sense of urgency among physicians post-ASN to treat earlier and more aggressively, a trend supported by the new KDIGO guidelines and Travere's data showing consistent efficacy across patient populations.